Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 11/2014

01-11-2014 | Research Article

TGF-beta induced RBL2 expression in renal cancer cells by down-regulating miR-93

Authors: J. Shi, Y. Zhuang, X. K. Liu, Y. X. Zhang, Y. Zhang

Published in: Clinical and Translational Oncology | Issue 11/2014

Login to get access

Abstract

Purpose

TGF-beta can induce G1 arrest via many mechanisms including up-regulating p21, p27, and Rb. However, as the member of Rb family, whether RBL2 is induced by TGF-beta treatment remains exclusive.

Methods

The expression of RBL2 and miR-93 after TGF-beta treatment was determined by quantitative real-time PCR and western blot. The growth of renal cancer cells was determined by CCK-8 assays and cell cycle was determined by PI staining. The binding of miR-93 on RBL2 3′-UTR was determined by double luciferase system.

Results

In renal cancer cells, TGF-beta treatment induced expression of RBL2 in a time- and concentration-dependent manner, and RBL2 mediated TGF-beta induced growth inhibition and cell cycle arrest in renal cancer cells. Furthermore, we found that miR-93 directly targeted RBL2 by binding to its 3′-UTR in renal cancer cells. Over-expression of miR-93 significantly reduced the expression of RBL2, whereas knock down of miR-93 up-regulated the expression of RBL2. More importantly, TGF-beta treatment inhibited miR-93 expression, which resulted in up-regulation of RBL2 after TGF-beta treatment.

Conclusion

TGF-beta induced RBL2 expression through down-regulating miR-93 in renal cancer cells. The newly identified TGF-beta/miR-93/RBL2 signal pathway reveals a new mechanism of TGF-beta induced growth arrest in renal cancer.
Appendix
Available only for authorised users
Literature
1.
2.
Brizzi MF, Dentelli P, Rosso A, Calvi C, Gambino R, Cassader M, et al. RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy. FASEB J. 2004;18:1249–51.PubMed
3.
Wolf G, Schroeder R, Zahner G, Stahl RA, Shankland SJ. High glucose-induced hypertrophy of mesangial cells requires p27(Kip1), an inhibitor of cyclin-dependent kinases. Am J Pathol. 2001;158:1091–100.PubMedCrossRefPubMedCentral
4.
Galliher AJ, Neil JR, Schiemann WP. Role of transforming growth factor beta in cancer progression. Future Oncol. 2006;2:743–63.PubMedCrossRef
5.
Sengupta S, Kundu S, Bhattacharyya A. Attenuation of Smad2 activity shows resistance to TGF-β signalling in mammary adenocarcinoma (MCF-7) cells. Cell Biol Int. 2013;37:449–57.PubMedCrossRef
6.
7.
Drabsch Y, ten Dijke P. TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012;31:553–68.PubMedCrossRef
8.
Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350–3.PubMedCrossRef
9.
Ramp U, Jaquet K, Reinecke P, Nitsch T, Gabbert HE, Gerharz CD. Acquisition of TGF-beta 1 resistance: an important progression factor in human renal cell carcinoma. Lab Invest. 1997;76:739–49.PubMed
10.
Shang D, Liu Y, Yang P, Chen Y, Tian Y. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel–Lindau tumor suppressor. Urology. 2012;79:966.e1–7.CrossRef
11.
Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, et al. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem. 2011;286:8655–65.PubMedCrossRefPubMedCentral
12.
Ewen ME. p53-dependent repression of cdk4 synthesis in transforming growth factor-beta-induced G1 cell cycle arrest. J Lab Clin Med. 1996;128:355–60.PubMedCrossRef
13.
Choi HH, Jong HS, Hyun Song S, You Kim T, Kyeong Kim N, Bang YJ. p130 mediates TGF-beta-induced cell-cycle arrest in Rb mutant HT-3 cells. Gynecol Oncol. 2002;86:184–9.PubMedCrossRef
14.
Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6:376–85.PubMedCrossRef
15.
Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13:272–86.PubMedCrossRef
16.
Ravitz MJ, Wenner CE. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. Adv Cancer Res. 1997;71:165–207.PubMedCrossRef
17.
Lewis BP, Burge CP, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.PubMedCrossRef
18.
Liang LH, He XH. Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy. Acta Pharmacol Sin. 2011;32:1311–20.PubMedCrossRefPubMedCentral
19.
Redova M, Svoboda M, Slaby O. MicroRNAs and their target gene networks in renal cell carcinoma. Biochem Biophys Res Commun. 2011;405:153–6.PubMedCrossRef
20.
Schaefer A, Stephan C, Busch J, Yousef GM, Jung K. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol. 2010;7:286–97.PubMedCrossRef
21.
Hata A, Davis BN. Control of microRNA biogenesis by TGFbeta signaling pathway—a novel role of Smads in the nucleus. Cytokine Growth Factor Rev. 2009;20:517–21.PubMedCrossRefPubMedCentral
22.
Petrocca F, Vecchione A, Croce CM. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res. 2008;68:8191–4.PubMedCrossRef
23.
Huang S, He X, Ding J, Liang L, Zhao Y, Zhang Z, et al. Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer. 2008;123:972–8.PubMedCrossRef
Metadata
Title
TGF-beta induced RBL2 expression in renal cancer cells by down-regulating miR-93
Authors
J. Shi
Y. Zhuang
X. K. Liu
Y. X. Zhang
Y. Zhang
Publication date
01-11-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 11/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1185-7

Other articles of this Issue 11/2014

Clinical and Translational Oncology 11/2014 Go to the issue

Educational series – Red Series

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer

Research Article

ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer

Research Article

Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib

Brief Research Article

Genetic disorders of pediatric MEN2A patients in the south of Spain

Research Article

Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer

Research Article

MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits